Skip to main content

Press releases

Go back

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101

Galimedix is proud to report that the inventor of the company’s groundbreaking technology for the treatment of Alzheimer’s disease and our esteemed co-founder, Prof. Ehud Gazit, has been honored with Germany’s prestigious Meitner-Humboldt Research Award

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD™ 2024 Conference

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need

Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer’s Disease

Planned Phase 2 Trial of Visual Function Improvement in iAMD Gains Support From Novel Analysis Of Microperimetry Endpoints

Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab

1
2
3